We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

30 hedge funds and large institutions have $8.17M invested in Protara Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

4% less capital invested

Capital invested by funds: $8.55M → $8.17M (-$379K)

3% less funds holding

Funds holding: 31 → 30 (-1)

6.84% less ownership

Funds ownership: 45.17% → 38.33% (-6.8%)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
6
Closed
3
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$3K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$78.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$23.4K
3
LPL Financial
LPL Financial
California
+$2.95K
4
UBS Group
UBS Group
Switzerland
+$1.17K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$336

Top Sellers

1
O
OrbiMed
New York
-$1.29M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$58.4K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$23.1K
4
Millennium Management
Millennium Management
New York
-$9.64K
5
Northern Trust
Northern Trust
Illinois
-$3.63K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$5.05M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$802K – – –
BC
3
Boxer Capital
California
$392K – – –
BBA
4
Baker Bros. Advisors
New York
$374K – – –
IC
5
Ikarian Capital
Texas
$353K – – –
PFMU
6
Privium Fund Management (UK)
United Kingdom
$225K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$212K +$78.4K +53,200 +89%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$147K – – –
BCM
9
Bridgeway Capital Management
Texas
$120K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$71.1K +$23.4K +15,892 +72%
BlackRock
11
BlackRock
New York
$64.3K -$422 -286 -0.8%
State Street
12
State Street
Massachusetts
$57.8K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$50.7K -$1.18K -800 -3%
Two Sigma Investments
14
Two Sigma Investments
New York
$47.1K -$3.24K -2,200 -8%
BFM
15
Boothbay Fund Management
New York
$35.4K – – –
Northern Trust
16
Northern Trust
Illinois
$34K -$3.63K -2,460 -12%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$33.6K – – –
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
$29.7K – – –
LPL Financial
19
LPL Financial
California
$22.5K +$2.95K +2,000 +20%
Millennium Management
20
Millennium Management
New York
$21.5K -$9.64K -6,541 -36%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$11K – – –
TRCT
22
Tower Research Capital (TRC)
New York
$8.13K -$672 -456 -10%
ACM
23
ADAR1 Capital Management
Texas
$4.11K +$3.23K +2,194 New
UBS Group
24
UBS Group
Switzerland
$1.72K +$1.17K +795 +657%
Wells Fargo
25
Wells Fargo
California
$1.07K +$6 +4 +0.7%
1
2

TARA Hedge Fund Activity: Q4 2023 in Review

30 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2023, worth a combined $8.17M — down 4.4% from $8.55M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TARA and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $78.4K. The largest seller was OrbiMed, exiting entirely with an estimated $1.29M sold.

  • 30 institutional investors held Protara Therapeutics (TARA) as of Q4 2023, down from 31 in Q3 2023.
  • Funds reported $8.17M of Protara Therapeutics stock for Q4 2023, down 4.4% quarter-over-quarter.
  • 2 funds opened new Protara Therapeutics positions in Q4 2023 and 3 closed out, a net change of -1 holder.
  • The largest Protara Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $78.4K added.
  • The largest Protara Therapeutics seller in Q4 2023 was OrbiMed, an estimated $1.29M sold.

Based on aggregated 13F filings for Q4 2023.